GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Cash from Discontinued Operating Activities

GILD (Gilead Sciences) Cash from Discontinued Operating Activities : $0 Mil (TTM As of Sep. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Gilead Sciences's Cash from Discontinued Operating Activities for the three months ended in Sep. 2024 was $0 Mil. It means Gilead Sciences received $0 Mil from discontinued investing activities. Gilead Sciences's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Sep. 2024 was $0 Mil.


Gilead Sciences Cash from Discontinued Operating Activities Historical Data

The historical data trend for Gilead Sciences's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cash from Discontinued Operating Activities Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash from Discontinued Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash from Discontinued Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Gilead Sciences Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Cash from Discontinued Operating Activities
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711